Paragon Capital Management Inc. acquired a new stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 9,954 shares of the company’s stock, valued at approximately $1,311,000. Neurocrine Biosciences comprises approximately 1.1% of Paragon Capital Management Inc.’s investment portfolio, making the stock its 23rd largest position.
A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. AQR Capital Management LLC grew its position in Neurocrine Biosciences by 83.7% in the 3rd quarter. AQR Capital Management LLC now owns 2,773,648 shares of the company’s stock worth $388,435,000 after purchasing an additional 1,263,633 shares during the period. Norges Bank purchased a new stake in Neurocrine Biosciences during the 4th quarter valued at $162,664,000. UBS Group AG lifted its holdings in shares of Neurocrine Biosciences by 169.8% during the 4th quarter. UBS Group AG now owns 983,528 shares of the company’s stock valued at $139,494,000 after buying an additional 618,956 shares during the period. Zurich Insurance Group Ltd FI bought a new position in shares of Neurocrine Biosciences during the 4th quarter valued at $65,162,000. Finally, Two Sigma Investments LP purchased a new position in shares of Neurocrine Biosciences in the 3rd quarter worth $48,791,000. Institutional investors own 92.59% of the company’s stock.
Insider Buying and Selling at Neurocrine Biosciences
In other news, Director Stephen A. Sherwin sold 25,000 shares of the firm’s stock in a transaction dated Friday, June 5th. The stock was sold at an average price of $165.32, for a total value of $4,133,000.00. Following the transaction, the director owned 15,860 shares of the company’s stock, valued at $2,621,975.20. This trade represents a 61.18% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Julie Cooke sold 36,937 shares of Neurocrine Biosciences stock in a transaction dated Tuesday, June 2nd. The shares were sold at an average price of $156.22, for a total value of $5,770,298.14. Following the transaction, the insider directly owned 22,374 shares in the company, valued at approximately $3,495,266.28. The trade was a 62.28% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 355,234 shares of company stock valued at $55,330,060 in the last ninety days. 4.60% of the stock is currently owned by company insiders.
Wall Street Analysts Forecast Growth
View Our Latest Research Report on NBIX
Neurocrine Biosciences Price Performance
NASDAQ:NBIX opened at $161.62 on Tuesday. Neurocrine Biosciences, Inc. has a one year low of $122.14 and a one year high of $169.57. The business has a fifty day moving average price of $149.13 and a 200-day moving average price of $140.84. The firm has a market capitalization of $16.25 billion, a price-to-earnings ratio of 24.90, a price-to-earnings-growth ratio of 1.19 and a beta of 0.39.
Neurocrine Biosciences Profile
Neurocrine Biosciences (NASDAQ: NBIX) is a biopharmaceutical company based in San Diego, California, focused on developing treatments for neurological, endocrine and neuropsychiatric disorders. Since its founding in 1992, the company has pursued a research‐driven strategy aimed at addressing unmet medical needs in movement disorders, reproductive health and central nervous system conditions. Neurocrine’s operations encompass drug discovery, clinical development and commercialization activities.
The company’s lead marketed product, Ingrezza™ (valbenazine), is indicated for the treatment of tardive dyskinesia, a movement disorder associated with long-term antipsychotic use.
Featured Stories
- Five stocks we like better than Neurocrine Biosciences
- Buy CrowdStrike Before the Stock Split? Here’s the Case
- Investors Are Buying Into Sweetgreen Again—Should They?
- Burlington Is Winning Over Shoppers But Investors Need Patience
- USA Today’s Digital Revival Is Gaining Steam, But With Plenty of Risk
Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
